

























1　平成10年（行ケ）401号（東京高判平13年 4 月25日）、平成 2年（ワ）12094号（東京地判平 4年10月23日）、平成10年（行
ケ）308号（東京高判平12年 7 月13日）、平成10年（行ケ）364号（東京高判平12年 2 月10日）等。これらは旧審査基準に
挙げられている。






ムされた特徴については何も述べていない。』（“Recognition of anticipation by a theory of inherency means that patent law 
permits the destruction of novelty based on information not explicitly contained in a prior art reference. Conceptually this can be 
viewed as either (1) an exception to the “single reference” component of the strict identity rule; or (2) an expansion of the strict 
identity rule such that the prior art reference’s “disclosure” can be considered inherent rather than explicit. The more realistic view is 
the former, for inherency cases typically involve resorting to information extrinsic to the allegedly anticipatory prior art reference. The 
















カルを除去するステップを含む、治療方法。』（“CL1. A method for treating skin sunburn comprising topically 
applying to the skin sunburn a fatty acid ester of ascorbic acid eﬀective to solubilize in the lipid-richlayers of the skin 
an amount eﬀective to scavenge therefrom free radicals present as a result of transfer of energy to the skin from the 
ultraviolet radiation which produced said sunburn.”）
　『クレーム 8．日光に曝された皮膚表面に対する日焼けダメージの予防方法であって、アスコルビン酸
の脂肪酸エステルの有効量を皮膚に局所的に適用するステップを含む、予防方法。』（“CL8. A method for 
preventing sunburn damage to exposed skin surfaces, comprising topically applying to said skin surfaces a fatty acid 















は注意を要する（Hilton Davis Chem. Co. v. Warner-Jenkinson Co., 62 F.3d 1512 (Fed. Cir. 1995)は、『anticipationの現在の意味
は異なる。 “anticipation”は、今や狭義の意味、すなわち、発明が新規性を失うということである。現在の法の下では、
先行技術の装置のいかなる差異も自明性で評価される。』（“the current meaning of “anticipation” is diﬀerent. “Anticipation” now 
carries a narrower meaning, namely, that the invention lacks novelty. Under the current statute, any diﬀerences from a prior art device 



































シクロプロピルアルキルエーテルを含む包装された製品。』（CL15. A packaged product comprising cyclopropyl 






5　“Under the principles of inherency, if the prior art necessarily functions in accordance with, or includes, the claims limitations, it 
anticipates.”… Moreover, “inherency is not necessarily coterminous with knowledge of those of ordinary skill in the art. Artisans of 
ordinary skill may not recognize the inherent characteristics or functioning of the prior art.”… Claim 1 of the ’693 patent recites a 
new use of the composition disclosed by Pereira, i.e., the treatment of skin sunburn. …Pereira is silent about any sunburn prevention 
or treatment beneﬁts, not to mention the mechanisms underlying such uses. If Pereira did teach sunburn prevention, as well as the 
mechanism behind that prevention, those teachings might suggest that Dr. Perricone’s sunburn treatment claims would have been 
obvious. However, those unrealized possibilities do not alter the analysis in this case where Pereira does not disclose topical 
application to skin sunburn. Unlike claim 1, claim 8 of the ’693 patent, …merely requires application of the composition to exposed 
skin surfaces. Because all skin surfaces are susceptible to sunburn damage, and because one can only realistically apply a composition 






























療のための新規な治療薬。』（“CL1. A new therapeutic product for the treatment of diseased tissue, comprising a 
condensation product of metacresolsulfonic acid condensed through an aldehyde.”）
　USPTOでの特許を否定するアピールの判断に対して、特許出願人が、『本件発明の組成物は公知である
としても、タンニング剤（日焼け促進剤）に使用されていたに過ぎない（“This product had long been 








8　“It is well settled that the application of particular printed matter to an old article cannot render the article patentable. … the mere 
labeling of an old composition as an insecticide does not make it a new or diﬀerent composition within the meaning of the patent 
statutes. The appealed claim, like those considered in In re Thuau, supra, represents an attempt to patent an old product on the basis of 
a statement that it is intended for a new use. Whether the statement of intended use appears merely in the claim or in a label on the 
product is immaterial so far as the question of patentability is concerned. … The issue here is whether an old composition can be 
patented as a composition on the basis of the mere statement of a new use. …In accordance with the patent statutes, an article or 
composition of matter, in order to be patentable, must not only be useful and involve invention, but it must also be new. If there is no 
novelty in an article or composition itself, then a patent cannot be properly granted on the article or composition, regardless of the use 
for which it is intended.”
9 　特許第4602922号の特許請求の範囲は『歯垢形成を抑制する効果を有することを特徴とし、歯垢形成を抑制するため
に用いるものである旨の表示をした、請求項 3記載の食品又は飲料。』である。















は、『特許されていない物品や長く使われてきた物質』（“unpatentable article or substance long in use”）を、
加工を加えない限り、用途が公知されている、いないに関わらず自由に利用できる）、b）同じ剤に二つの
特許を認めることによる市場の混乱が生じる12、c）本件の使用（use）は、『発明は新規で有用な機械、製
造物、組成物または、これらの新規で有用な改良』（“the invention or discovery of any new and useful art, 













the combination of the following parts above described, to wit: the core and bridge, or guide-piece, with the cylinder, 
the piston, the chamber and the die, when used to form pipes of metal, under heat and pressure, in the manner set 
11　“To allow a patent for an old composition without change in any way, merely because it may be used for a speciﬁed purpose, would 
result in a situation where two compositions of exactly the same character could be sold by merchants to consumers, but if one of the 
compositions was not made by the patentee or his assignee or licensee, the merchant might be liable to suit for infringement if the 
composition was used by the purchaser for therapeutic purposes, and the user would certainly be liable to such a suit. In our opinion 
the patent laws do not contemplate that two identical substances or devices may be legally sold side by side, only one of which is the 
subject of a valid patent, ... .That appellant has made a valuable discovery in the new use of the composition here involved we have no 
doubt, and it is unfortunate for him if he cannot make claims adequate to protect such discovery, but to hold that every new use of an 
old composition may be the subject of a patent upon the composition would lead to endless confusion and go far to destroy the 
beneﬁts of our patent laws.”







14　Le Roy v. Tatham, 55 U.S. 156 (1852).
用途発明における特許性について （舘）
5
forth, or in any other manner substantially the same.”）。
　特許権者（原告）が特許侵害に関し被告を地裁に訴えたところ、地裁は、『オリジナリティは機械の新
規性にあるのではなく、新たに発見した原理を現実に適用したことであり、それによって有用な生産物、
すなわち、キャストパイプと異なる精錬されたパイプを作り出したことにある。』（“the originality did not 
consist in the novelty of the machinery, but in bringing a newly discovered principle into practical application, by 


























『もし、昔からよく知られており、新しい目的に使われるだけなら、特許性は得られない』（“If it is old and 
well known, and applied only to a new purpose, that does not make it patentable.”）として特許を否定した。
　なお、本件には Dissentが提出されている。Dissentは、『彼らは、新規なものとして、単独に主張して
いるわけではないし、他の目的や他のいかなる方法で使われることを主張しているわけではない。明細書
で指摘した目的と方法のために適用されるときにのみ、その新規性を主張している』（“They do not claim it 
as new separately, or when used for any other purpose, or in any other way; but claim it, only, when applied for the 
15　“It is admitted, that a principle is not patentable. A principle, in the abstract, is a fundamental truth; an original cause; a motive; 
these cannot be patented, as no one can claim in either of them an exclusive right. Nor can an exclusive right exist to a new power, 
should one be discovered in addition to those already known. …A new property discovered in matter, when practically applied, in the 
construction of a useful article of commerce or manufacture, is patentable; but the process through which the new property is 
developed and applied, must be stated, with such precision as to enable an ordinary mechanic to construct and apply the necessary 
process. This is required by the patent laws of England and of the United States, in order that when the patent shall run out, the public 
may know how to proﬁt by the invention. …Leaden pipes are the same, the metal being in no respect diﬀerent.  Any diﬀerence in 
form and strength must arise from the mode of manufacturing the pipes. The new property in the metal claimed to have been 
discovered by the patentees, belongs to the process of manufacture, and not to the thing made.”
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媒で処理することを含む、ジヒドロピランのポリマーの製造のためのプロセス。』（“CL1. A process for the 
production of polymers of dihydropyran which comprises treating dihydropyran in the liquid phase and under 
substantially anhydrous conditions with a Friedel-Crafts catalyst.”）









16　Boulton v. Watt, 2 H. Bl. 453 (1765). 
















　『クレーム 2．159℃で溶融するβ（4-ヒドロキシ -3,5-ジヨードフェニル）αフェニルプロピオン酸』（“CL 
2. The beta - (4-hydroxy-3,5-diiodophenyl) -alpha-phenyl propionic acid which melts at 159 degrees c.”）
　『クレーム 4． 化学式…のヒドロキシジフェニルカルボン酸のポリヨード誘導体。』（“CL 4. Polyiodo 


















18　“In the brief for appellants before us it is said, in substance, that the tribunals of the Patent Oﬃce did not question the production of 
a new chemical polymer by the process disclosed by appellants, and that those tribunals did not question the identiﬁcation of such 
polymer. The statement so made in the brief for appellants is accurate, but the matters suggested as not being questioned by the 
tribunals of the Patent Oﬃce were not considered by those tribunals on their per se patentable merits, because they held that no use for 
the products claimed to be developed by the processes had been shown in the speciﬁcation. …It is our view that no "hard and fast" 
ruling properly may be made ﬁxing the extent of the disclosure of utility necessary in an application, but we feel certain that the law 
requires that there be in the application an assertion of utility and an indication of the use or uses intended. It was never intended that 
a patent be granted upon a product, or a process producing a product, unless such product be useful.”
19　岩田弘ほか『物質特許の知識』33頁（通商産業調査会、1975）。
20　Schering Corp. v. Gilbert, 153 F.2d 428 (2nd Cir.1946).
21　“The product of Claim 2 would have the needed characteristics for an improved contrast agent for use in gall bladder radiology 
though now that the solution of the problem has been found in the end product of a fairly simple series of chemical reactions it is easy 
unjustly to belittle what was done unless proper consideration is given to the following potent evidence of the fact that inspiration 
筑波法政第79号（2019）
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　本件は2,4,6-トリアルキルピラゾイド [4,3-d]-4,5,6,7-テトラヒドロ p-5,7-ピリミジン -5,7-ジオン
（2,4,6-TRIALKYLPYRAZOLO [4,3-d]-4,5,6,7-TETRAHYDROPYRIMIDINE-5,7-DIONES）に関する発明であ
り、争点となったクレームは概略以下に示される。
　『クレーム 1． 特定の化学構造を有する合成物であり、…Rは 1以上 5以下の炭素数を有する低級アル
カリラジカルである化合物。』（“CL1. A compound of the structural formula … wherein R is a lower alkyl radical 









beyond the ordinary was needed. …We think a precise claim for a new and useful compound which has been adequately disclosed in 
the speciﬁcations is no less valid because the compound happens to be a new molecule. …Claim 4 covers by means of a broad elastic 
chemical formula which allows for the greatest number theoretically possible for molecular changes within the benzene ring, not only 
the compounds illustrated by way of examples in the speciﬁcations but also every possible variation of them which might result from 
further experiment. The speciﬁcations do not support that sort of claim but are no more at best than suggestions for experiment. Such 
experiment might be practically endless and futile as a matter of fact. And it might yield surprisingly useful results which, if this claim 
were valid, would be futile as a matter of law during the life of the patent.” 
22　本事案では、胆嚢造影法に利用する優れた造影剤が望まれていたが、19年目にして本事案の発明者により作り出され、
市場で独占的に利用され、被告にも模倣されたことが紹介されている。







































24　“From the foregoing cases it will be seen that this and other courts, both before and after the enactment of section 103, have 
determined the unobviousness and patentability of new chemical compounds by taking into consideration their biological or 
pharmacological properties. Nine of the ten cases above considered, directly and indirectly, involved such properties. Patentability has 
not been determined on the basis of the obviousness of structure alone. In fact, where patentability was found in the above cases it was 
found in spite of close similarity of chemical structure, often much closer similarity than we have here. …And the patentability of the 
thing does not depend on the similarity of its formula to that of another compound but of the similarity of the former compound to the 
latter. There is no basis in law for ignoring any property in making such a comparison. An assumed similarity based on a comparison 
of formulae must give way to evidence that the assumption is erroneous. …Patentability is not resolved conclusively even where 
unexpected or unobvious beneficial properties are established to exist in novel members of a homologous series over prior art 
members, as the circumstances of the case may require a consideration of other factors.”















　『クレーム 1．元素95。』（“CL1. Element 95.”）
　USPTOでのアピールの判断は、本件の物質はフェルミらの引用発明において、inherentlyに製造されて
いたとして特許を否定した。これに対して、特許出願人が、引用発明では『未知で、濃縮されていないア
イソトープの量は、存在するとしても、検知不能である。』（“This amount of an unknown, unconcentrated 













26　“Patentability is not resolved conclusively even where unexpected or unobvious beneﬁcial properties are established to exist in 
novel members of a homologous series over prior art members, as the circumstances of the case may require a consideration of other 
factors. …In eﬀect, the nature of homologues and the close relationship the physical and chemical properties of one member of a 
series bears to adjacent members is such that a presumption of unpatentability arises against a claim directed to a composition of 
matter, the adjacent homologue of which is old in the art. The burden is on the applicant to rebut that presumption by a showing that 
the claimed compound possesses unobvious or unexpected beneﬁcial properties not actually possessed by the prior art homologue. 
…To those skilled in the chemical art, one homologue is not such an «advance» over an adjacent member of the series as requires 
invention, unless the beneﬁcial properties realized in the new homologue lie clearly outside of the expectations which knowledge of 
his science would inform the trained chemist should be inherent in the product. … it is sufficient to state that more than a new 
advantage of a product must be discovered to lend it patentability….”
27　In re Seaborg, 51 C.C.P.A. 1109 (1964).
28　“If the earlier disclosure oﬀers no more than a starting point for further experiments, if its teaching will sometimes succeed and 
sometimes fail, if it does not inform the art without more how to practice the new invention, it has not correspondingly enriched the 
store of common knowledge, and it is not an anticipation. …There is no positive evidence that americium was produced inherently in 
the natural uranium fuel by the operation of the reactor for the times and at the intensity mentioned in the exemplary statement relied 
upon by the Patent Oﬃce. The calculations, however, that the maximum amount of americium-241 which could have been produced 
by the operation of the reactor disclosed in the Fermi Patent for 100 days at 500 kilowatts would have been one billionth of one gram 
(1/1,000,000,000 gram), show that the element, if produced was produced in the most minute quantities. …The possibility that 























… 。』（“CL1. As a new article of manufacture the acetyl salicylic acid having the formula: …being when crystallized 
















identiﬁed, would preclude the application of the Fermi patent as a reference to anticipate the present invention.”
29　Farbenfabriken of Elberfeld Co. v. Kuehmsted, 171 F. 887 (Cir.1909).
30　“The question for decision is whether it required invention to discover the improved purifying process, whether the patentee 
obtained a new article of manufacture, or whether the prior art shows the same substance. …The prior art suggests a water puriﬁcation, 
and Hoﬀman a waterless one. …That the discovery of the patentee was a most valuable one clearly appears.  Even a small amount of 
free salicylic acid injures the stomach; …Unless the patent law is clearly unfavorable, his discovery should be protected. Hrauths 
product was not beneﬁcially capable of performing the function of a patented article, while Hoﬀman was the ﬁrst to make a successful 
one. He took a comparatively worthless substance and changed it into a valuable one. It was he, and not Kraut or the other famous 






明者は、『相対的に価値のない物質を価値ある物に変えた』（“He took a comparatively worthless substance and 
changed it into a valuable one.”）であるとして、その有用性を認め、特許を有効であると判断した。アセチ
ルサリチル酸は化合物であり、遊離サリチル酸との混合物として存在していたとしても、世の中に既に存











　『クレーム1 下記構造式…又は薬理学的に許容される塩の化合物であって、Xは Clか Fである化合物。』






















サリチル酸と同じである。』（“The crystalline mass is substantially acetyl salicylic acid. Almost the whole of it is the compound 
acetyl salicylic acid completely formed. For practical purposes the whole may be taken to be and be used as acetyl salicylic acid. Its 
general and therapeutical characteristics are the same those of pure salicylic acid.”）として特許を否定した。





















　本件は、抗鬱剤として有益な医薬物質である塩酸塩半水和物（hydrochloride hemihydrate （PHC 
hemihydrate））に関する発明であり、争点となったクレームは以下に示される。
　『クレーム1 結晶性パロキセチン塩酸塩半水和物。』（“CL1.Crystalline paroxetine hydrochloride 
hemihydrate.”）
　特許権者（原告）が特許侵害に関し被告を地裁に訴えたところ、被告が製造する paroxetine 
hydrochloride anhydrate （PHC anhydrate））は、クレーム 1を侵害しないとした。これに対して、原告、被
告の両者が控訴したのが本件事案である。なお、特許権者の発明に係る PHC hemihydrateと、被告の製造






PHC hemihydrateを含まない PHC anhydrateを米国で作ることができないことを示す必要はなく、
ただ、先行技術に開示された内容が、先行技術で示された操作から得られる自然法則にしたがっ
た結果がクレームされた物であることを示せばよい。記録によれば、明確かつ説得力ある証拠に
33　“a prior art reference may anticipate without disclosing a feature of the claimed invention if that missing characteristic is 
necessarily present, or inherent, in the single anticipating reference. … Thus, recognition by a person of ordinary skill in the art before 
the critical date of the ’716 patent is not required to show anticipation by inherency. …In the context of accidental anticipation, DCL is 
not formed accidentally or under unusual conditions when loratadine is ingested. The record shows that DCL necessarily and 
inevitably forms from loratadine under normal conditions. ...The record also shows that DCL provides a useful result, because it 
serves as an active non-drowsy antihistamine. In sum, this court’s precedent does not require a skilled artisan to recognize the inherent 
characteristic in the prior art that anticipates the claimed invention. …the use of loratadine would infringe claims 1 and 3 of the ’716 
patent covering the metabolite DCL. …An identical metabolite must then anticipate if earlier in time than the claimed compound. …
Anticipation does not require the actual creation or reduction to practice of the prior art subject matter; anticipation requires only an 
enabling disclosure. …Finally, this court’s conclusion on inherent anticipation in this case does not preclude patent protection for 
metabolites of known drugs. With proper claiming, patent protection is available for metabolites of known drugs.”
34　Burk, D.L. & Lemley, M.A., Inherency in William and Mary Law Review, Vol. 47, No. 2, 371, 379  (2005).
35　SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331 (Fed. Cir. 2003).
筑波法政第79号（2019）
14








hemihydrateを含むと解釈したのに対して、第二審では、引用発明には PHC hemihydrateを生み出す PHC 
anhydrateを作る方法（enabling manner）が開示され、また、検知不能な量以下しか PHC hemihydrateを含
まない PHC anhydrateを作る方法は見つかっていないなどの事実により、原告の発明は引用発明により
inherently anticipatedされるとして、特許を無効とした。
　 本件において、PHC anhydrateを製造すること自体は public domainにあるものである。本来 public 






















36　“if the prior art infringes now, logically the prior art should have anticipated the claim before the ﬁling of the ’723 patent. …Apotex 
did not need to prove that it was impossible to make PHC anhydrate in the United States that contained no PHC hemihydrate, but 
merely that “the disclosure [of the prior art] is suﬃcient to show that the natural result ﬂowing from the operation as taught [in the 
prior art] would result in” the claimed product. …Because the record contains clear and convincing evidence that production of PHC 
anhydrate in accordance with the ’196 patent inherently results in at least trace amounts of PHC hemihydrate, this court holds that the ’
196 patent inherently anticipates claim 1 of the ’723 patent under 35 U.S.C. § 102 (b).”
37　本件は方法クレーム（method）ではあるものの、実際には用途発明とは異ならない。『日焼けした皮膚を処置するため』
（“for treating skin sunburn”）との限定は使用する者の意思に依存するものであって、剤に日焼け治療剤との明記がないか






い。これに対し、Le Roy v. Tathamでは processであるなら、新たな要件を付加せずとも、特許が認められ
る余地があるという点で、In re Thuauとは異なる事案である。Dissentが指摘するように、本件発明は特
定の目的で使用され、そのような目的では従来使用されていなかったことを考えると、公衆は『何も変え



















（“inventive genius skill and not mere skill of the calling”）が必要な発明ではないとされ、特許が否定されてい
る。















報センター、1969）。）、PRESIDENTS ADDRESS, “THEIR INFLUENCE ON TRADE AND INDUSTRY”, JOURNAL OF THE 
SOCIETY OF CHEMICAL INDUSTRY, No.13, Vol.XXI, 897, 897 (1902))。
41　岡田吉美「新規性・進歩性、記載要件について（上）数値限定発明を中心にして」特許研究 No41、28頁、36頁（2006）。


















で処方例が開示されていたにすぎない。後者では、PHC anhydrateを製造すると、その一部が PHC 
hemihydrateが変換される。この PHC hemihydrateは製造設備に残留し、次の PHC anhydrateを製造する際











組成物（use of the old composition）という意味で、new useというカテゴリに分類される43。物として、公
知の物とは、使用目的が異なる点を除き、外形的には区別ではないため、『二重の用途』（“double use”又








43　判例上は、new useは new use of the old compositionに限られず、公知の物や方法を組み合わせて得られる新規な組合せ
（combination）の発明や、公知の物や方法の置換（substitution）の発明に対しても適用されてきた。旧法の§4886では、
発明は『新規で有益な技法、機械、組成物又は、それらの新規で有益な改良』（“any new and useful art, machine, 




























44　SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331 (Fed. Cir. 2003).
45　Comm’r of Patents v. Deutsche Gold-Und-Silber-Scheideanstalt Vormals Roessler, 397 F.2d 656の Opinionは『特許性は構造的
に自明であることだけを基礎としては決められない。自明な分子の改良は公知の特性に対して新規な特性か優れた特性
と結びついたとき、特許性を得る。』（“patentability is not determined on the basis of structural obviousness alone. Obvious 
molecular modiﬁcation coupled with a showing of novel properties or superiority of known properties can establish patentability.”）
とする。
46　かつての日本や米国は、世界公知ではなかった（相対的新規性）。旧米国特許法 Pre-AIA　102（b） では、発明が『こ
の国において公衆の前で使用されあるいは販売された』（in public use or on sale in this country）場合には認めないとしてお
り、裏を返すと米国外にいて実施された物質があっても、特許になり得たことを示している。




特許を認める立場からは重要と思われる。この点では、英国の事案であるMERRELL DOW PHARMACEUTICALS INC 
AND OTHERS v. H.N. NORTON & CO. LIMITED, UKHL14（1995）も大差はない。事案としては、Schering v. Genevaと同
様であるが、剤自体は過去形で記載され実際に製造されたことは理解できるものの、抗ヒスタミン剤として効果がある
と記載されているだけで、本発明の明細書において実際に摂取したことは記載されていない。
48　inherencyは、『可能性や蓋然性』（“probabilities or possibilities）”では成立しないとされる（Hansgrig v. Kemmer,102 F.2d 
212, 214 C.C.P.A. (1939)）。Schering v. Genevaでは、引用発明の捉え方に関し評価が分かれている。Burk, D.L. & Lemley, 
M.A., supra note 34 at 381は、『公衆は必然的にその代謝物の利益を得ることになる』（“public would necessarily obtain the 
beneﬁt of the metabolite”）として Opinionに賛成の立場である。Mueller & Chisum, supra note 2 at 1150は、本件の実施例は
現在形で記載され、『Scheringの事案は過度の実験を求めるもので反対である』（“we disagree with the Schering court’s use of 
the nonstaturtory “undue experimentation”）とし Opinionと反対の立場をとる。Timothy R. Holbrook, PATENT ANTICIPATION 


















　米国における inherencyの事案として CAFCでしばしば引用される Titanium v. Banner51は、チタンをベー
スとするアロイの発明である。クレームは『チタンべースのアロイであり、実質、0.6～0.9％のニッケル、
0.2～0.4％のモリブデン、最大量0.2％までの鉄と、バランスとしてのチタンからなり、高塩水条件の環境
下で高い耐腐食性を有するアロイ。』（“A titanium base alloy consisting essentially by weight of about 0.6％ to 
0.9％ nickel, 0.2％ to 0.4％ molybdenum, up to 0.2％ maximum iron, balance titanium, said alloy being 
















v. GenevaとSmithKline v. Apotex ）は、引用発明に明示的には開示されていない新たな物を発明としている。
確かに、引用発明においてはその新たな物を『認識』していないが、引用発明を実施すると必然的に後の
49　仲村義平「用途発明における『物の未知の属性を発見すること』の意味の考察」パテント Vol. 67、 No. 3、102頁、104
頁（2014）。
50　特許・実用審査基準（平成27年 9 月公表）第 III 部 第2 章 第4 節 特定の表現を有する請求項等についての取扱い、3.1.3 
3.1.1 や3.1.2 の考え方が適用されない、又は通常適用されない場合、7頁。
51　Titanium Metals Corp. v. Banner, 778 F.2d 775 (Fed. Cir. 1985).
52　“Congress has not seen ﬁt to permit the patenting of an old alloy, known to others through a printed publication, by one who has 
discovered its corrosion resistance or other useful properties, or has found out to what extent one can modify the composition of the 
alloy without losing such properties.” なお、CAFCは inherencyの事案として本判例をたびたび引用している。しかし、




























　Cont’l Can v. Monsanto57は、コンテナに関する発明の事案である。クレーム要件の『リブが空洞であると








53　Tilghman v. Proctor, 102 U.S. 707 (1880).
54　“We do not regard the accidental formation of fat acid in Perkins’s steam cylinder from the tallow introduced to lubricate the piston 
(if the scum which rose on the water issuing from the ejection pipe was fat acid) as of any consequence in this inquiry.  What the 
process was by which it was generated or formed was never fully understood.”
55　Eibel Process Co. v. Minn. & Ont. Paper Co., 261 U.S. 45 (1923).
56　 “we ﬁnd no evidence that any pitch of the wire, used before Eibel, had brought about such a result as that sought by him, and in the 
second place if it had done so under unusual conditions, accidental results, not intended and not appreciated, do not constitute 
anticipation.”
57　Cont’l Can Co. v. Monsanto Co., 948 F.2d 1264 (Fed. Cir. 1991).
58　“To serve as an anticipation when the reference is silent about the asserted inherent characteristic, such gap in the reference may be 
ﬁlled with recourse to extrinsic evidence. Such evidence must make clear that the missing descriptive matter is necessarily present in 
the thing described in the reference, and that it would be so recognized by persons of ordinary skill. … Inherency, however, may not 












































しも不可能でないことが示唆される。ただし、米国特許法35 U.S.C. §101が特許の対象とするのは、“any new and useful, 










　『クレーム 1． RNA群を標準化し拡大するためのキットであり、そのキットはクレーム 1の方法を述
べる指示書を含む… 。』（“CL1. A kit for normalizing and amplifying an RNA population, said kit comprising 













　『クレーム 1． 呼吸器疾患を有する患者の治療方法であり、患者に、1日 1回を超えない頻度において、
ブテソニド組成物の噴霧物を連続的投与する処方で与える方法。』（“CL1. A method of treating a patient 
suffering from a respiratory disease, the method comprising administering to the patient a nebulized dose of a 
budesonide composition in a continuing regimen at a frequency of not more than once per day.”）
　『クレーム29． 呼吸器疾患を治療するためのキットであり、そのキットは、（a）密閉容器に含まれる0.05
～15mgのブテソニドと溶媒を含むブテソニド組成物と、（b） 1日 1 回を超えない頻度において、ブテソニ
ド組成物の噴霧物を連続的投与する処方を指示するラベルからなるキット。』（“CL1. A kit for treating 
respiratory diseases, the kit comprising (a) a budesonide composition in a sealed container, the composition 
containing 0.05 mg to 15 mg budesonide and a solvent, and (b) a label indicating administration by nebulization in a 






61　In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004).
62　“All that the printed matter does is teach a new use for an existing product. As the Gulack court pointed out, “where the printed 
matter is not functionally related to the substrate, the printed matter will not distinguish the invention from the prior art in terms of 
patentability.” Id. If we were to adopt Ngai’s position, anyone could continue patenting a product indeﬁnitely provided that they add a 
new instruction sheet to the product.”
63　さらに、米国においては訴訟で内部文章等を互いに開示しあう discovery制度がある。この制度により、本来の意図が
明らかになることは、日本の場合よりも多いと思われる。
64　AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042 (Fed. Cir. 2010).
65　“This court has generally found printed matter to fall outside the scope of § 101. …This court considered the printed matter 
exception in Ngai, a case similar to the one now before us. … Concluding that this content was not functionally related to the kit, the 
Board found that the claim was anticipated by the prior art. This court aﬃrmed, rejecting the argument that the addition of new printed 




























66　ROBERT PATRICK MERGES,JOHN FITZGERALD DUFFY, DUFFY, J.F., MERGES, R.P., Patent law and policy: cases and 
materials. 6th edn.. Patent law and policy: cases and materials. 6th edn., LexisNexis, 373-377 (2013)は、用途発明（use patent）
の権利行使の困難さに対して、米国特許法271条による寄与侵害又はクラスアクションをより利用しやすいものにするこ
とを提案する。
67　Warner-Lambert Company LLC v. Generics （UK） Ltd t/a Mylan and another, UKSC 2017/0078 （2018）は、スイスタイプクレー
ムという特殊な use claimの特許権侵害が争われた英国の事案である。争点となったクレームは、以下に示される。
 　『クレーム1. 疼痛を治療するための医薬組成物の製造のための（3S）-3-（アミノメチル）-5メチルヘキサン酸…の使用。』
（“CL1. Use of (S)-3-(aminomethyl)-5-methylhexanoic acid…for the preparation of a pharmaceutical composition for treating pain.”）
 　サプション卿は、foreseeability testに一定の評価をしつつ、the outward presentation test、すなわち、ラベルや患者の情報
を記載したリフレット等外形的な表示で判断すべきとして非侵害とした。平嶋竜太「医薬用途発明のクレーム解釈と記
載要件」別冊 Patent Vol. 71、109 頁、126頁（2018）控訴院判決の『当業者は、クレームにおける“for”という言葉を、
プレガバリンを使う製造の行為と、痛みを処理するために、末端のユーザーへの究極的かつ意図的な使用との結びつき
をするものとして理解する。』（“the skilled person would understand the word “for” in the claim to be providing a link between the 











うものはそのニーズがあるにも関わらず（2016年 5 月20日 薬事・食品衛生審議会 化粧品・医薬部外品部会 「議事録」（平









新規（new）の物、すなわち、new manufactureであり、その裏返しとして19世紀初頭には new useとして
同じ物の用途違いの発明を否定している。英国の19世紀の判例である Losh v. Hague70では、『当該薬をそ
のような新規な目的のために適用することは特許の主題ではない。薬は製造物であり、それを作り合成す
ることが特許の主題である。しかし、その薬は公知であり、新しい適用の発見は製造物には該当しない。




　当時、英米の特許法には Novelty（米国では“any new and useful art”）の規定しかなかった。しかし、『特
許性を有する新規性』（“Patentable Novelty (inventiveness、unobviousness)”）は特許法制定当初より要求され
ている。機械や装置の発明は、積み木のように組み合わせられる場合も多く、結果の如何に関わらず、組
み合わせ自体は（後から見ると）容易であり、単に公知のものを組み合わせたに過ぎない（a new use of 
an old thing or an old process）という結論に容易につながるのは想像に難くない。このような判断手法は、
Cuno v. Automatic72において、『創造性を有する天才のひらめき』（“the ﬂash of creative genius”）とする高レ
ベルの基準を要求したことで批判を受けるに至り、1952年の特許法改正につながったことはよく知られて
いる。その改正により、新たに103条として unobviousnessの規定が入り、『特許は、発明がなされた態様



















70　Losh v. Hague, 1 W.P.C. 202, 208 n. (f) (1838).
71　“the application of that medicine to such a new purpose would not be the subject-matter of letters patent. The medicine is a 
manufacture, and the making or compounding it might be the subject of a patent; but the medicine being known, the discovery of any 
new application is not any manner of manufacture. Cases of this kind are well described by the term ‘double use;’ and under such 
circumstances it is truly said, there cannot be a patent for a double or new use of a known thing, because such use cannot be said to 
lead to any manner of new manufacture.”
72　Cuno Engineering Corp v. Automatic Devices Corp.,314 U.S. 84 (1941).
73　岩田弘「西ドイツ改正特許法の解説」物質特許の知識』情報管理587頁、587頁（日本科学技術情報センター、1969）。

































INDUSTRY, No.13, Vol.XXI, 897, 897 (1902).
74　Beauchamp, C. “Patenting nature: a problem of history”, Stan.Tech.L.Rev., Vol. 16, 257, 284 (2012).
75　ジョーゼフ・ギーボン（佐藤雅也）『巨悪の同盟　ヒトラーとドイツ企業の罪と罰』46頁（原書房，2011）。
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